During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Latest Ratings for APLS
DateFirmActionFromTo Mar 2022Goldman SachsMaintainsBuy Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022Raymond JamesMaintainsStrong Buy